ReviewDrug design, development and therapy2015

Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.

Aleksander Lenert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.